Patents, commons, and innovation in psychedelic drug development
As universities and companies stake intellectual property claims on psychedelic compounds, applications, and data sets, a robust dialogue has emerged about the way patents and data exclusivity may accelerate or constrain innovation, competition, and access to care. Join us for a nuanced consideration of the economic and cultural implications of intellectual property rights within the psychedelic ecosystem.
Share: Patents, commons, and innovation in psychedelic drug development
Facebook
Twitter
LinkedIn
Email